...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Microbiology >Optimizing Antimicrobial Susceptibility Test Reporting
【24h】

Optimizing Antimicrobial Susceptibility Test Reporting

机译：优化抗菌药物敏感性试验报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A meeting of clinical microbiologists, representing a diverse group of practice settings, together with representatives from industry partners, discussed the pitfalls of current practices for testing and reporting antimicrobial susceptibility test results. The participants in this session identified several needs. Regarding what antibiotics to test, the discussants noted that the CLSI M100 documents must be readily accessible to all those who need them and presented in a way that is easily understood. Engineering controls (e.g., software programs) are needed that incorporate intrinsic resistance and susceptibility information and contain pathways that would allow the reporting of antibiotics for only those body locations where the antibiotic reaches therapeutic concentrations. These programs should be linked with the patient electronic medical record (EMR) and flag the physician or clinical pharmacist using an active alert messenger when testing reveals that the antibiotic(s) that the patient is receiving may not be optimal or de-escalation of the antibiotic treatment regimen is indicated. Guidelines for the practice of cascade reporting are needed and should be developed to assist laboratories in the identification and reporting of therapeutic and cost-effective antimicrobials. Personalized antibiotic reporting (PAR) software programs are needed that would deduce the optimal antibiotic for each individual patient based on a number of clinical and laboratory features. These would include the following: (i) organism identification; (ii) MIC; (iii) patient-specific factors such as weight, immune status, allergies, creatinine clearance, and albumin level; (iv) site of infection; (v) desired method of dosing (bolus versus continuous infusion); (vi) patient convenience (oral versus intravenous); (vii) drug interactions; and (viii) cost.
机译：代表不同实践组的临床微生物学家会议与来自行业合作伙伴的代表一起，讨论了当前实践中用于测试和报告抗微生物药敏性测试结果的陷阱。本次会议的参与者确定了一些需求。关于要测试的抗生素，讨论者指出，所有需要它们的人都必须易于获得CLSI M100文件，并以易于理解的方式出示。需要工程控制（例如软件程序），其结合内在抗性和药敏性信息，并包含允许仅报告抗生素达到治疗浓度的那些身体部位的抗生素的报告途径。这些程序应与患者电子病历（EMR）关联，并在测试显示患者所接受的抗生素可能不是最佳或降级时，使用主动警报器标记医师或临床药剂师。指示抗生素治疗方案。需要级联报告的实践指南，应制定指南以帮助实验室鉴定和报告治疗性和成本有效的抗菌剂。需要个性化的抗生素报告（PAR）软件程序，该程序将根据许多临床和实验室特征为每个患者推导出最佳抗生素。这些将包括以下内容：（i）识别生物; （ii）MIC; （iii）特定于患者的因素，例如体重，免疫状况，过敏，肌酐清除率和白蛋白水平; （iv）感染部位; （v）所需的给药方法（推注与连续输注）; （vi）患者的便利性（口服还是静脉注射）; （vii）药物相互作用; （viii）费用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号